This relatively new Prolia side effect, hypocalcemia, first came to our attention in late 2022 with the release of this November 22, 2022 document, “FDA Drug Safety Communication: FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)”. From that November 2022 FDA Drug Safety … [Read more...]
EzriCare Artificial Tears Case Reports Involving Vision Loss
A recent edition of the JAMA Ophthalmology medical journal presented two EzriCare Artificial Tears case reports about serious infection and vision loss associated with these over-the-counter (OTC) eye drops from Global Pharma. The two EzriCare Artificial Tears case reports are set forth in these March 2023 JAMA Ophthalmology medical journal … [Read more...]
EzriCare and Delsam Products Recall: March 2023 Update
Here is the most recent information from the US Centers for Disease Control and Prevention (CDC) about the EzriCare and Delsam products recall for case reports associated with bacterial contamination: As of March 1, 2023, CDC, in partnership with state and local health departments, identified 64 patients in 13 states (CA, CO, CT, FL, IL, NJ, NM, … [Read more...]
Delsam Pharma Artificial Eye Ointment Recall February 2023
In late February the FDA announced a Delsam Pharma Artificial Eye Ointment recall by Global Pharma a day after warning not to use this eye product due to a potential Artificial Eye Ointment contamination problem. We are investigating cases involving hospitalization, death, or permanent vision loss from an eye infection due to the Artificial Eye … [Read more...]
EzriCare and Delsam Pharma’s Eye Drops Products Recall
In early February 2023 there was an artificial tears lubricant eye drops products recall involving EzriCare and Delsam Pharma’s Artificial Tears. As a standard practice, when a drug company announces a recall, market withdrawal, or safety alert, the FDA posts the company’s announcement as a public service. Here is the Global Pharma Healthcare … [Read more...]
EzriCare Artificial Tears Eye Infections Warnings
There is detailed information about the in this Centers for Disease Control and Prevention (CDC) Outbreak and Patient Notifications article, “Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa Associated with Artificial Tears”, including this fact: As of January 31, 2023, CDC, in partnership with state and local health departments, … [Read more...]
Valtrex Side Effect: DRESS Skin Reaction, Can be Fatal
According to the Health Product InfoWatch December 2022 edition released by Health Canada on December 22, 2022, cases of Valtrex-associated DRESS have been reported as a Valtrex side effect. Further, therein, it is reported that GlaxoSmithKline Inc. has updated the Canadian product monograph for Valtrex to add information about the risk of … [Read more...]
Tepezza Medical Articles About Drug Side Effects Focus on Hearing Issues
We are investigating possible Tepezza drug injury cases where the patient, while using Tepezza, started to experience hearing loss or other hearing problems. Specifically, those Tepezza hearing issues include: Hearing loss, ranging from impairment to deafness (Hypoacusis and Sensorineural Hearing Loss) Sound or noise sensitivity that makes … [Read more...]
Tepezza Hearing Loss, Other Tepezza Hearing Problems May be Irreversible and Permanent
Tepezza hearing loss and other Tepezza hearing problems have been reported by medical doctors and patients since this treatment for Thyroid Eye Disease was approved by the FDA in 2020. Those Tepezza hearing problems have involved various medical diagnosis types, including: Hypoacusis: hearing loss ranging from impairment to … [Read more...]
FDA AdComm: Copiktra Risk-Benefit Profile No Longer Favorable as a Third-Line CLL/SLL Treatment
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted 8-4 against the Copiktra risk-benefit profile, as reported in this September 23, 2022, Endpoint News article, “FDA adcomm takes down Secura Bio’s leukemia drug after final trial results show potential OS detriment”. From that recent news report about the safety of Copiktra … [Read more...]